Literature DB >> 28284315

Long-term outcome of patients with nonspecific pleurisy at medical thoracoscopy.

Yuan Yang1, Yan-Bing Wu1, Zhen Wang1, Xiao-Juan Wang1, Li-Li Xu1, Zhao-Hui Tong1, Huan-Zhong Shi2.   

Abstract

BACKGROUND: Medical thoracoscopy is an effective and safe procedure for diagnosing pleural effusions of undetermined causes. But there are still a part of patients with pleural effusions were diagnosed as nonspecific pleurisy when no specific biopsy results were found after undergoing thoracoscopic biopsy. The long-term outcome of these patients is unclear, and anxieties about undiagnosed malignancy persist.
METHODS: Between July 2005 and June 2014, medical thoracoscopy using the semi-rigid instrument was performed and pleural biopsy was taken in 833 patients with pleural effusions. Fifty-two patients diagnosed with nonspecific pleurisy with available follow-up data were included in the present study and their medical records were reviewed.
RESULTS: Fifty-two patients (31 men and 21 women) were included. Mean follow up was 35.5 ± 40.9 months (range, 1-143 months). No specific diagnosis was established in 21 (40.4%) of the patients. Eight of 52 patients with nonspecific pleurisy (15.4%) were subsequently diagnosed with pleural malignancies. 23 of 52 patients (44.2%) were diagnosed as benign diseases. The recurrence of pleural effusion during followed-up and pleural nodules or plaques found in medical thoracoscopy was associated with malignant disease.
CONCLUSION: Patients with nonspecific pleurisy after medical thoracoscopy should be closely monitored, especially in those patients with the recurrence of pleural effusion during followed-up, pleural nodules or plaques found in medical thoracoscopy. One year of clinical follow-up for patients found to have nonspecific pleurisy is likely sufficient.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Nonspecific pleurisy; Outcome; Thoracoscopy

Mesh:

Year:  2017        PMID: 28284315     DOI: 10.1016/j.rmed.2017.01.005

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

1.  Incidence of malignancy and survival in patients with idiopathic pleuritis.

Authors:  Simon Bertram Reuter; Paul Frost Clementsen; Uffe Bodtger
Journal:  J Thorac Dis       Date:  2019-02       Impact factor: 2.895

2.  Clinical long-term outcome of non-specific pleuritis (NSP) after surgical or medical thoracoscopy.

Authors:  Georgia Karpathiou; Stavros Anevlavis; Olivier Tiffet; Francois Casteillo; Mousa Mobarki; Valentine Mismetti; Paschalis Ntolios; Andreas Koulelidis; Tiffany Trouillon; Nicolas Zadel; Sirine Hathroubi; Michel Peoc'h; Marios E Froudarakis
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 2.895

3.  Development and validation of the PET-CT score for diagnosis of malignant pleural effusion.

Authors:  Min-Fu Yang; Zhao-Hui Tong; Zhen Wang; Ying-Yi Zhang; Li-Li Xu; Xiao-Juan Wang; Wan Li; Xiu-Zhi Wu; Wen Wang; Yu-Hui Zhang; Tao Jiang; Huan-Zhong Shi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-03-22       Impact factor: 9.236

Review 4.  Pleural effusion related to IgG4.

Authors:  Yoriyuki Murata; Keisuke Aoe; Yusuke Mimura
Journal:  Curr Opin Pulm Med       Date:  2019-07       Impact factor: 3.155

5.  The Intrapleural Bridge Connection is One of the Reasons for Unknown Localized Pleural Adhesion.

Authors:  Qihua Gu; Xinhao Deng; Zhao Li; Jing Wang; Chengping Hu; Shuhua Lei; Xiaoling Cai
Journal:  Int J Gen Med       Date:  2021-04-20

6.  Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.

Authors:  Li-Li Xu; Yuan Yang; Zhen Wang; Xiao-Juan Wang; Zhao-Hui Tong; Huan-Zhong Shi
Journal:  BMC Pulm Med       Date:  2018-04-03       Impact factor: 3.317

Review 7.  Inflammation of the Pleural Cavity: A Review on Pathogenesis, Diagnosis and Implications in Tumor Pathophysiology.

Authors:  Georgia Karpathiou; Michel Péoc'h; Anand Sundaralingam; Najib Rahman; Marios E Froudarakis
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.